ABSTRACT
BACKGROUND AND AIMS: Conjugated linoleic acid (CLA) has been used to improve body composition in weight management. However, clinical trial results are inconsistent and limited among Asians. We aimed to investigate the effect of CLA on body composition of Chinese adults with elevated body fat percentage. METHODS AND RESULTS: In this double-blind, randomized, placebo-controlled trial, 66 Chinese adults (aged 18-45 years old, 37.9% male) with elevated body fat percentage were provided with 3.2 g/day CLA (n = 33) or 3.2 g/day placebo (sunflower oil; n = 33) for 12 weeks. Both groups received lifestyle counseling, featured with low fat and low sugar diet, and moderate physical activity. Body composition was measured using dual-energy X-ray absorptiometry at the baseline and end of the trial. Sixty-four participants finished this study. Compared with the placebo group, the CLA group showed increased trunk muscle mass (MM) (0.6 ± 1.7 vs. -0.3 ± 1.2 kg, P = 0.019). Among those with an adherence score higher than 0.80 (n = 56, 87.5%), a greater increase in both total and trunk MM was observed in the CLA group (both P < 0.05). Moreover, the effect on MM appeared to be more evident in men, those with a body mass index <25 kg/m2, or those with higher self-rated physical activity. CONCLUSIONS: In Chinese adults with elevated body fat percentage, 3.2 g/day CLA supplementation may be effective in preserving MM, especially in the trunk region. REGISTRATION: This study was registered at ClinicalTrials.gov as NCT03915808 on April 9, 2019.
Subject(s)
Adiposity , Body Composition/drug effects , Dietary Supplements , Linoleic Acids, Conjugated/therapeutic use , Muscle, Skeletal/drug effects , Obesity/drug therapy , Adolescent , Adult , China , Dietary Supplements/adverse effects , Double-Blind Method , Female , Humans , Linoleic Acids, Conjugated/adverse effects , Male , Middle Aged , Muscle, Skeletal/physiopathology , Obesity/diagnosis , Obesity/physiopathology , Treatment Outcome , Young AdultABSTRACT
Mixtures of the two major conjugated linoleic acid (CLA) isomers trans-10,cis-12-CLA and cis-9,trans-11-CLA are used as over the counter supplements for weight loss. Because of the reported adverse effects of CLA on insulin sensitivity in some mouse studies, we sought to compare the impact of dietary t10c12-CLA and c9t11-CLA on liver, adipose tissue, and systemic metabolism of adult lean mice. We fed 8 week-old C57Bl/6J male mice with low fat diets (10.5% Kcal from fat) containing 0.8% t10c12-CLA or c9t11-CLA for 9 or 38 days. Diets containing c9t11-CLA had minimal impact on the endpoints studied. However, 7 days after starting the t10c12-CLA diet, we observed a dramatic reduction in fat mass measured by NMR spectroscopy, which interestingly rebounded by 38 days. This rebound was apparently due to a massive accumulation of lipids in the liver, because adipose tissue depots were visually undetectable. Hepatic steatosis and the disappearance of adipose tissue after t10c12-CLA feeding was associated with elevated plasma insulin levels and insulin resistance, compared to mice fed a control diet or c9t11-CLA diet. Unexpectedly, despite being insulin resistant, mice fed t10c12-CLA had normal levels of blood glucose, without signs of impaired glucose clearance. Hepatic gene expression and fatty acid composition suggested enhanced hepatic de novo lipogenesis without an increase in expression of gluconeogenic genes. These data indicate that dietary t10c12-CLA may alter hepatic glucose and lipid metabolism indirectly, in response to the loss of adipose tissue in mice fed a low fat diet.
Subject(s)
Glucose/metabolism , Linoleic Acids, Conjugated/pharmacology , Lipid Metabolism/drug effects , Liver/drug effects , Adipose Tissue/drug effects , Adipose Tissue/physiology , Animals , Dyslipidemias/chemically induced , Fatty Acids/metabolism , Gene Expression Regulation/drug effects , Glucose Intolerance/chemically induced , Insulin Resistance , Isomerism , Linoleic Acids, Conjugated/adverse effects , Lipodystrophy/chemically induced , Lipodystrophy/genetics , Lipogenesis/drug effects , Liver/metabolism , Male , Mice, Inbred C57BL , Non-alcoholic Fatty Liver Disease/chemically inducedABSTRACT
Milk fat depression (MFD) is characterized by a reduction in the content of milk fat, presumably caused by the anti-lipogenic effects of rumen biohydrogenation intermediates, such as trans-10 cis-12 conjugated linoleic acid (CLA). In this study, RNA-Seq technology was used to help elucidate the mammary responses involved in CLA-induced MFD in lactating ewes. To this end, we compared the milk somatic cell transcriptome of ewes suffering from CLA-induced MFD with control ewes (i.e., those without MFD), as well as with ewes fed a diet supplemented with fish oil (FO-MFD) that we previously reported affects the mammary transcriptome. In the differential expression analysis between CLA-MFD and controls, we identified 1,524 differentially expressed genes (DEGs), whereas 653 were detected between CLA- and FO-MFD groups. Although this article focuses on lipid metabolism, CLA affected the expression of many genes related to other biological processes, especially immunity. Among the 55 genes shared by both MFD conditions, some genes linked to fatty acid synthesis, such as ACACA, AACS, ACSS2, or ACSS3, were downregulated. In addition, this study provides a list of candidate genes that are not usually considered in the nutrigenomics of MFD but that may act as key regulators of this syndrome in dairy ewes.
Subject(s)
Gene Expression Profiling/veterinary , Linoleic Acids, Conjugated/adverse effects , Lipid Metabolism/drug effects , Milk/drug effects , Animals , Dietary Supplements/adverse effects , Female , Fish Oils/administration & dosage , Fish Oils/adverse effects , Gene Expression Regulation/drug effects , Gene Regulatory Networks/drug effects , Linoleic Acids, Conjugated/administration & dosage , Milk/chemistry , Sequence Analysis, RNA/veterinary , SheepABSTRACT
BACKGROUND & AIMS: The liver is the main organ regulating metabolism. In spite of that, few studies examine liver metabolism in cachexia, a wasting syndrome associated with increased morbidity and mortality in cancer. Cachexia induces major metabolic disruption, inflammation and fat and lean mass loss. We have previously shown impairment of hepatic lipid metabolism in cancer cachexia that contributes to the aggravation of the symptoms. The present study addresses the effects of Conjugated Linoleic Acid supplementation upon liver lipid metabolism in cachectic rats. METHODS: Male Wistar rats were randomly assigned to control groups (C) receiving 0.9 NaCl (Placebo CP); or to groups supplemented with sunflower oil (CSF), supplemented with CLA (CCLA), or still, to tumour bearing animals (T) receiving NaCl (TP), sunflower oil (TSF), or CLA (TCLA). Supplementation (0.5 ml) by gavage was carried out for 14 days. Body weight, dietary intake, glucose, cholesterol and triacylglycerol plasma content, liver glycogen and triacylglycerol content and mRNA expression of liver carnitine palmitoyltransferase I and II (CPT I and II), as well as microsomal triglyceride transfer protein (MTP), liver fatty acid-binding protein (L-FABP), peroxisome proliferator-activated receptor-alpha (PPAR-alpha), and apolipoprotein B (apoB), were assessed. RESULTS: Liver CPT II activity was reduced in all groups, when compared with CP. Hepatic mRNA expression of MTP, apoB and FABP was reduced in TCLA, when compared with all groups. TCLA also presented increased hepatic and plasma triacylglycerol content, when compared with all T groups. Adipose tissue-derived inflammatory factors were assessed. No differences among the groups were observed in regard to Retro Peritoneal Adipose Tissue cytokine (IL-1ß, IL-6, and TNF-α) protein content and expression, with the exception of IL-10 in tumour-bearing animals. In the Epididymal Adipose Tissue, the inflammatory cytokines were augmented in TCLA, compared with all other groups. CONCLUSION: CLA supplementation fails to promote the re-establishment of hepatic lipid metabolism in tumour-bearing animals, and therefore is not recommended in cancer-related cachexia.
Subject(s)
Cachexia , Linoleic Acids, Conjugated , Lipid Metabolism/drug effects , Liver , Neoplasms/complications , Adipose Tissue/chemistry , Adipose Tissue/metabolism , Animals , Cachexia/etiology , Cachexia/metabolism , Dietary Supplements , Inflammation/chemically induced , Inflammation/metabolism , Linoleic Acids, Conjugated/adverse effects , Linoleic Acids, Conjugated/pharmacology , Lipids/analysis , Liver/chemistry , Liver/drug effects , Liver/metabolism , Male , Rats , Rats, WistarABSTRACT
Background: Natural antioxidants in foods may be used in prevention and treatment of oxidative stress and inflammation in COPD. Therefore, this study aimed to evaluate the effect of conjugated linoleic acid (CLA) supplement as natural antioxidants on oxidative stress levels, and MMP2 and MMP9 serum levels in COPD patients. Materials and methods: This clinical trial study was conducted on 90 (supplement group=45 and control group=45) COPD patients in Ardabil city, Iran, in 2015. After obtaining written consent, general information was collected from each patient using a validated and reliable questionnaire. Supplement group received 3.2 g of CLA and those in the control group were given 3.2 g of placebo for 6 weeks on a daily basis. Fasting blood samples were taken from all of the patients for testing of malondialdehyde (MDA), MMP2, and MMP9 levels at the beginning and end of the study. Data were analyzed using Kolmogorov-Smirnov test, independent samples t-test, paired sample t-test, chi-square test, and ANOVA. Results: There were no significant differences between the two groups with regard to mean age, smoking status, and serum level of MDA at the beginning of the study. In the supplement group, the serum level of MDA decreased significantly at the end of the 6th week compared to that in the beginning of the study (p=0.0004), while in the placebo group, the difference was found to be insignificant. The serum level of MMP9 decreased significantly in the supplement group, while in the placebo group its level increased significantly as compared to that at the beginning of the study (p<0.05). The serum levels of MMP2 indicated no significant differences between the two groups neither at the beginning nor at the end of the study. Conclusion: These findings indicated that CLA supplementation may be helpful for COPD patients through inhibiting the production of oxidative stress and controlling MMP9 serum levels.
Subject(s)
Antioxidants/therapeutic use , Linoleic Acids, Conjugated/therapeutic use , Matrix Metalloproteinase 2/blood , Matrix Metalloproteinase 9/blood , Oxidative Stress/drug effects , Pulmonary Disease, Chronic Obstructive/drug therapy , Adult , Aged , Aged, 80 and over , Antioxidants/adverse effects , Biomarkers/blood , Double-Blind Method , Female , Humans , Iran , Linoleic Acids, Conjugated/adverse effects , Male , Malondialdehyde/blood , Middle Aged , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/enzymology , Time Factors , Treatment OutcomeABSTRACT
Dietary supplementation with conjugated linoleic acid (CLA) has been proposed for weight management and to prevent gut inflammation. However, some animal studies suggest that supplementation with CLA leads to the development of nonalcoholic fatty liver disease. The aims of this study were to test the efficiency of CLA in preventing dextran sulfate sodium (DSS)-induced colitis, to analyze the effects of CLA in the liver function, and to access putative liver alterations upon CLA supplementation during colitis. So, C57BL/6 mice were supplemented for 3 weeks with either control diet (AIN-G) or 1% CLA-supplemented diet. CLA content in the diet and in the liver of mice fed CLA containing diet were accessed by gas chromatography. On the first day of the third week of dietary treatment, mice received ad libitum a 1.5%-2.5% DSS solution for 7 days. Disease activity index score was evaluated; colon and liver samples were stained by hematoxylin and eosin for histopathology analysis and lamina propria cells were extracted to access the profile of innate cell infiltrate. Metabolic alterations before and after colitis induction were accessed by an open calorimetric circuit. Serum glucose, cholesterol, triglycerides and alanine aminotransaminase were measured; the content of fat in liver and feces was also accessed. CLA prevented weight loss, histopathologic and macroscopic signs of colitis, and inflammatory infiltration. Mice fed CLA-supplemented without colitis induction diet developed steatosis, which was prevented in mice with colitis probably due to the higher lipid consumption as energy during gut inflammation. This result suggests that CLA is safe for use during gut inflammation but not at steady-state conditions.
Subject(s)
Colitis/diet therapy , Linoleic Acids, Conjugated/pharmacology , Non-alcoholic Fatty Liver Disease/chemically induced , Alanine Transaminase/blood , Animals , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Colitis/chemically induced , Colitis/prevention & control , Colon/drug effects , Colon/immunology , Colon/pathology , Dextran Sulfate/toxicity , Dietary Supplements , Female , Immunity, Innate/drug effects , Immunity, Innate/physiology , Linoleic Acid/metabolism , Linoleic Acids, Conjugated/adverse effects , Liver/cytology , Liver/drug effects , Liver/metabolism , Mice, Inbred C57BLABSTRACT
BACKGROUND/OBJECTIVES: Conjugated linoleic acid (CLA) is a polyunsaturated fatty acid with attractive biological activities. Numerous studies have been conducted on the inflammation-lowering effects of CLA in in vitro and animal models. However, the effects of CLA treatment on the inflammatory markers in humans are controversial. Therefore, the objective of this study was to perform a systematic review and meta-analysis on controlled clinical trials (RCT) assessing the effects of CLA supplementation on the circulating inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). SUBJECTS/METHODS: The literature search of RCTs was performed using Pubmed/Medline, Scopus, ScienceDirect, Web of science, Cochrane, and Google Scholar databases from inception to March 2017. Weighted mean differences were estimated and the pooled effect size was calculated by a random effects model. RESULTS: Of the 427 identified studies, eleven RCTs, including 420 subjects were included in the statistical analysis. Findings suggested that CLA supplementation increased blood levels of CRP by 0.89 mg/l (95% CI: 0.11, 1.68; P = 0.025) and TNF-α levels by 0.39 pg/ml (95% CI: 0.23, 0.55; P < 0.0001). However, blood IL-6 levels were marginally decreased by 0.32 pg/ml (95% CI: -0.71, 0.07; P = 0.11) following CLA supplementation. There was a significant heterogeneity for the impact of CLA on CRP and IL-6, but not TNF-α. CONCLUSIONS: This meta-analysis showed that CLA supplementation may increase inflammatory markers (CRP and TNF-α). There are concerns about using CLA supplementation as an anti-obesity agent among the obese population for at least a short duration.
Subject(s)
Biomarkers/blood , Inflammation/blood , Linoleic Acids, Conjugated/adverse effects , C-Reactive Protein/analysis , Dietary Supplements , Humans , Interleukin-6/blood , Linoleic Acids, Conjugated/pharmacology , Linoleic Acids, Conjugated/therapeutic use , Obesity/drug therapy , Randomized Controlled Trials as Topic , Tumor Necrosis Factor-alpha/bloodABSTRACT
Caloric restriction (CR) is one of the most promising strategies for weight loss but is associated with loss of lean mass, whereas compounds such as trans-10,cis-12 conjugated linoleic acid (t10-c12 CLA) have been promoted as antiobesity agents. To compare the mechanisms of weight reduction by CR and t10-c12 CLA, body composition, glucose control, and characteristics of adipose tissue with respect to cell turnover (stem cells and preadipocytes, apoptosis and autophagy) and Tbx-1 localization were examined in obese db/db mice and lean C57BL/6J mice undergoing CR or fed CLA isomers (0.4% w/w c9-t11 or t10-c12) for 4 weeks. Our findings show that the t10-c12 CLA reduced whole-body fat mass by decreasing all fat depots (visceral, inguinal, brown/interscapular), while CR lowered both whole-body fat and lean mass in obese mice. t10-c12 CLA elevated blood glucose in both obese and lean mice, while glycemia was not altered by CR. The adipocyte stem cell population remained unchanged; however, t10-c12 CLA reduced and CR elevated the proportion of immature adipocytes in obese mice, suggesting differential effects on adipocyte maturation. t10-c12 CLA reduced apoptosis (activated caspase-3) in both obese and lean mice but did not alter autophagy (LC3II/LC3I). Nuclear Tbx-1, a marker of metabolically active beige adipocytes, was greater in the adipose of t10-c12 CLA-fed animals. Thus, weight loss achieved via t10-c12 CLA primarily involves fat loss and more cells with Tbx-1 localized to the nucleus, while CR operates through a mechanism that reduces both lean and fat mass and blocks adipocyte differentiation.
Subject(s)
Adipogenesis , Adiposity , Anti-Obesity Agents/therapeutic use , Caloric Restriction , Dietary Supplements , Linoleic Acids, Conjugated/therapeutic use , Obesity/diet therapy , Adipose Tissue, Beige/metabolism , Adipose Tissue, Beige/pathology , Adipose Tissue, Brown/metabolism , Adipose Tissue, Brown/pathology , Adipose Tissue, White/metabolism , Adipose Tissue, White/pathology , Adult Stem Cells/metabolism , Adult Stem Cells/pathology , Animals , Anti-Obesity Agents/adverse effects , Apoptosis , Biomarkers/metabolism , Caloric Restriction/adverse effects , Dietary Supplements/adverse effects , Linoleic Acids, Conjugated/adverse effects , Male , Mice, Inbred C57BL , Mice, Mutant Strains , Obesity/metabolism , Obesity/pathology , Random Allocation , T-Box Domain Proteins/metabolism , Weight LossABSTRACT
BACKGROUND: COPD patients are susceptible to anorexia, reduction of caloric intake, weight loss, and malnutrition. One of the possible mechanisms is the increase of inflammatory markers such as interleukin 1ß (IL1ß), is highly correlated with anorexia. Considering the anti-inflammatory role of conjugated linoleic acid (CLA), this study aimed to investigate the effect of CLA supplementation on the nutritional status of COPD patients. PATIENTS AND METHODS: In a double-blind clinical trial, 93 COPD patients who volunteered to participate in the study and who filled out a written consent form, were randomly assigned to control or supplementation groups. The patients in the supplementation group received 3.2 g of CLA on a daily basis for 6 weeks, while those in the control group received placebo on a daily basis for 6 weeks. For IL1ß assessment, the patients' anthropometric indices and appetite score were checked and their blood samples were collected both before and after the treatment. Moreover, in order to investigate the changes in the caloric intake trend during the study, their dietary intake levels were assessed using 24-hour dietary recall, 3 days a week at the onset, in the 4th week, and at the end of the study. Eventually, 90 patients completed the study. RESULTS: The results demonstrated a significant increase in appetite score (P=0.001), average caloric intake (P=0.01), and macronutrient intake (P<0.05), while a significant decrease was observed in the serum level of IL1ß among the patients of the supplementation group (P=0.008). Meanwhile, although the supplementation group's body mass index was also higher on completion, compared to their own initial state as well as to that in the control group, the differences were not significant (P=0.13). CONCLUSION: The findings of this research indicate that the consumption of CLA supplementation can be effective in regulating the appetite and improving the nutritional status of patients suffering from COPD through adjusting the serum level of IL1ß.
Subject(s)
Appetite Regulation/drug effects , Appetite Stimulants/therapeutic use , Linoleic Acids, Conjugated/therapeutic use , Nutritional Status/drug effects , Pulmonary Disease, Chronic Obstructive/drug therapy , Adult , Aged , Aged, 80 and over , Appetite Stimulants/adverse effects , Biomarkers/blood , Body Mass Index , Diet Records , Dietary Supplements/adverse effects , Double-Blind Method , Energy Intake/drug effects , Forced Expiratory Volume , Humans , Inflammation Mediators/blood , Interleukin-1beta/blood , Iran , Linoleic Acids, Conjugated/adverse effects , Lung/physiopathology , Male , Middle Aged , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/physiopathology , Time Factors , Treatment OutcomeABSTRACT
Previously, it was reported that conjugated linoleic acid (CLA) with exercise training potentially improved endurance capacity via the peroxisome proliferator-activated receptor δ (PPARδ)-mediated mechanism in mice. This study determined the role of exercise and/or CLA in endurance capacity and PPARδ-associated regulators. Male 129Sv/J mice were fed either control (soybean oil) or CLA (0.5%) containing diets for 4 weeks and were further divided into sedentary or training regimes. CLA supplementation significantly reduced body weight and fat mass independent of exercise during the experimental period. Endurance capacity was significantly improved by CLA supplementation, while no effect of exercise was observed. Similarly, CLA treatment significantly increased expressions of sirtuin 1 and PPARγ coactivator-1α, up-stream regulators of PPARδ, in both sedentary and trained animals. With respect to downstream markers of PPARδ, CLA up-regulated the key biomarker needed to stimulate mitochondrial biogenesis, nuclear respiratory factor 1. Moreover, CLA supplementation significantly induced overall genes associated with muscle fibers, such as type I (slow-twitch) and type II (fast twitch). Taken together, it suggests that CLA improves endurance capacity independent of mild-intensity exercise via PPARδ-mediated mechanism.
Subject(s)
Dietary Supplements , Gene Expression Regulation , Linoleic Acids, Conjugated/administration & dosage , Muscle, Skeletal/metabolism , PPAR gamma/agonists , Performance-Enhancing Substances/administration & dosage , Physical Endurance , Adiposity , Animals , Biomarkers/metabolism , Dietary Supplements/adverse effects , Energy Intake , Energy Metabolism , Linoleic Acids, Conjugated/adverse effects , Male , Mice, 129 Strain , Mitochondria, Muscle/metabolism , Mitochondrial Dynamics , Nuclear Respiratory Factor 1/agonists , Nuclear Respiratory Factor 1/genetics , Nuclear Respiratory Factor 1/metabolism , Organelle Biogenesis , PPAR gamma/genetics , PPAR gamma/metabolism , Performance-Enhancing Substances/adverse effects , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/agonists , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/genetics , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism , Random Allocation , Sirtuin 1/chemistry , Sirtuin 1/genetics , Sirtuin 1/metabolism , Weight GainABSTRACT
Obesity is the most widespread nutritional disease in the United States. Developing effective and safe strategies to manage excess body weight is therefore of paramount importance. One potential strategy to reduce obesity is to consume conjugated linoleic acid (CLA) supplements containing isomers cis-9, trans-11 and trans-10, cis-12, or trans-10, cis-12 alone. Proposed antiobesity mechanisms of CLA include regulation of (a) adipogenesis, (b) lipid metabolism, (c) inflammation, (d) adipocyte apoptosis, (e) browning or beiging of adipose tissue, and (f) energy metabolism. However, causality of CLA-mediated responses to body fat loss, particularly the linkage between inflammation, thermogenesis, and energy metabolism, is unclear. This review examines whether CLA's antiobesity properties are due to inflammatory signaling and considers CLA's linkage with lipogenesis, lipolysis, thermogenesis, and browning of white and brown adipose tissue. We propose a series of questions and studies to interrogate the role of the sympathetic nervous system in mediating CLA's antiobesity properties.
Subject(s)
Adipose Tissue, Beige/metabolism , Anti-Obesity Agents/therapeutic use , Dietary Supplements , Evidence-Based Medicine , Linoleic Acids, Conjugated/therapeutic use , Models, Biological , Obesity/diet therapy , Adipogenesis , Adipose Tissue, Beige/immunology , Adipose Tissue, Beige/pathology , Adipose Tissue, Brown/immunology , Adipose Tissue, Brown/metabolism , Adipose Tissue, Brown/pathology , Adipose Tissue, White/immunology , Adipose Tissue, White/metabolism , Adipose Tissue, White/pathology , Adiposity , Animals , Anti-Obesity Agents/administration & dosage , Anti-Obesity Agents/adverse effects , Anti-Obesity Agents/metabolism , Apoptosis , Dietary Supplements/adverse effects , Energy Metabolism , Humans , Insulin Resistance , Linoleic Acids, Conjugated/administration & dosage , Linoleic Acids, Conjugated/adverse effects , Linoleic Acids, Conjugated/metabolism , Lipogenesis , Obesity/immunology , Obesity/metabolism , Obesity/pathology , Oxidative Stress , ThermogenesisABSTRACT
BACKGROUND: Conjugated linoleic acid (CLA) reduces body weight (BW), body fat mass (BFM), and increases or maintains lean body mass in animals. However, the results concerning the effect of CLA on weight reduction in humans are contradictory. The present study aimed to evaluate the effect of CLA supplementation on the BW and anthropometric parameters (waist and hip circumferences) in overweight and obese adult women. METHODS: A total of 74 subjects (BMI: 28-42 kg/m2) were included in a double blind, placebocontrolled trial. Subjects were randomized into two groups, those supplemented with either 3.0 g/d CLA or with placebo (sunflower oil) for 12 weeks. RESULTS: CLA significantly decreased the hip circumferences compared to placebo (p = 0.016209), but had no effect on body weight, BMI, or waist circumference. The number of subjects with a reduction in hip circumference in the CLA group was significantly larger compared to that in the placebo group (p = 0.0017; NNT= 2.65; CI [6.27-1.685]). CONCLUSIONS: In conclusion, our findings do not support the hypothesis that 12 weeks CLA supplementation, as dosed in the present study, is effective for body weight reduction in overweight and obese women. However, its local action in decreasing the hip circumference seems to be encouraging and suggests that CLA may represent an attractive dietary supplement.
Subject(s)
Anti-Obesity Agents/therapeutic use , Dietary Supplements , Linoleic Acids, Conjugated/therapeutic use , Obesity/diet therapy , Overweight/diet therapy , Adult , Anti-Obesity Agents/adverse effects , Body Mass Index , Body Size , Dietary Supplements/adverse effects , Double-Blind Method , Female , Hip , Humans , Linoleic Acids, Conjugated/adverse effects , Middle Aged , Patient Dropouts , Poland , Waist Circumference , Weight LossABSTRACT
BACKGROUND: Adverse effects of industrially produced trans fatty acids (iTFAs) on the risk of coronary artery disease are well documented in the scientific literature; however, effects of naturally occurring trans fatty acids (TFAs) from ruminant animals (rTFA), such as vaccenic acid (VA) and cis-9,trans-11 conjugated linoleic acid (c9,t11-CLA), are less clear. Although animal and cell studies suggest that VA and c9,t11-CLA may be hypocholesterolemic and antiatherogenic, epidemiologic data comparing rTFAs and iTFAs are inconsistent, and human intervention studies have been limited, underpowered, and not well controlled. OBJECTIVE: We determined the effects of VA, c9,t11-CLA, and iTFA, in the context of highly controlled diets (24 d each), on lipoprotein risk factors compared with a control diet. RESULTS: We conducted a double-blind, randomized, crossover feeding trial in 106 healthy adults [mean ± SD age: 47 ± 10.8 y; body mass index (in kg/m(2)): 28.5 ± 4.0; low-density lipoprotein (LDL) cholesterol: 3.24 ± 0.63 mmol/L]. Diets were designed to have stearic acid replaced with the following TFA isomers (percentage of energy): 0.1% mixed isomers of TFA (control), â¼3% VA, â¼3% iTFA, or 1% c9,t11-CLA. Total dietary fat (34% of energy) and other macronutrients were matched. Total cholesterol (TC), LDL cholesterol, triacylglycerol, lipoprotein(a), and apolipoprotein B were higher after VA than after iTFA; high-density lipoprotein (HDL) cholesterol and apolipoprotein AI also were higher after VA. Compared with control, VA and iTFA both increased TC, LDL cholesterol, ratio of TC to HDL cholesterol, and apolipoprotein B (2-6% change; P < 0.05); VA also increased HDL cholesterol, apolipoprotein AI, apolipoprotein B, and lipoprotein(a) (2-6% change; P < 0.05), whereas iTFA did not. c9,t11-CLA lowered triacylglycerol (P ≤ 0.01) and had no effect on other lipoprotein risk factors. CONCLUSIONS: With respect to risk of cardiovascular disease, these results are consistent with current nutrition labeling guidelines, with the requirement of VA, but not c9,t11-CLA, to be listed under TFA on the Nutrition Facts Panel. This trial was registered at clinicaltrials.gov as NCT00942656.
Subject(s)
Cholesterol, LDL/agonists , Dietary Fats, Unsaturated/adverse effects , Hypercholesterolemia/etiology , Linoleic Acids, Conjugated/adverse effects , Oleic Acids/adverse effects , Plant Oils/adverse effects , Trans Fatty Acids/adverse effects , Adult , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Cholesterol/agonists , Cholesterol/blood , Cholesterol, LDL/blood , Cross-Over Studies , Double-Blind Method , Female , Humans , Hydrogenation , Hypercholesterolemia/blood , Hypercholesterolemia/physiopathology , Hypertriglyceridemia/blood , Hypertriglyceridemia/etiology , Hypertriglyceridemia/physiopathology , Male , Middle Aged , Plant Oils/chemistry , Risk Factors , Triglycerides/agonists , Triglycerides/bloodABSTRACT
Synthetic supplements of conjugated linoleic acid (CLA) containing 50:50 mixture of cis-9, trans-11 and trans-10, cis-12 CLA isomers have been commercialized in some places for reducing body fat. However the safety of this CLA mixture is controversial and in some countries the CLA usage as food supplement is not authorized. Changes in insulinemic control and serum lipids profile are potential negative effects related to consumption of CLA mixture. The present study aimed to evaluate the effects of a diet containing mixture of cis-9, trans-11 and trans-10, cis-12 CLA on prevention of obesity risk as well as on potential side effects such as insulin resistance and dyslipidemia in Wistar rats. Thirty male Wistar rats were randomly assigned to the following dietary treatments (n=10/group), for 60 days: Normolipidic Control (NC), diet containing 4.0% soybean oil (SO); High Fat-Control (HF-C), diet containing 24.0% SO; High Fat-synthetic CLA (HF-CLA), diet containing 1.5% of an isomeric CLA mixture (Luta-CLA 60) and 22.5% SO. Luta-CLA 60 (BASF) contained nearly 60% of CLA (cis-9, trans-11 and trans-10, cis-12 CLA at 50:50 ratio). The HF-CLA diet contained 0.3% of each CLA isomer. HF-CLA diet had no effect on dietary intake and body composition. HF-CLA-fed rats had lower levels of PPARγ protein in retroperitoneal adipose tissue, hyperinsulinemia compared to HF-C-fed rats, hyperglycemia compared to NC-fed rats while no differences in glycemia were observed between NC and HF-C groups, increased HOMA index and higher levels of serum HDL cholesterol. Thus, feeding rats with a high fat diet containing equal parts of cis-9, trans-11 and trans-10, cis-12 CLA isomers had no effect on body composition and induced insulin resistance. Despite HF-CLA-fed rats had increased serum HDL cholesterol levels, caution should be taken before synthetic supplements containing cis-9, trans-11 and trans-10, cis-12 CLA are recommended as a nutritional strategy for weight management.
Subject(s)
Body Composition/drug effects , Cholesterol, HDL/blood , Dietary Supplements , Insulin Resistance , Linoleic Acids, Conjugated/adverse effects , Linoleic Acids, Conjugated/pharmacology , Animals , Dyslipidemias , Hyperglycemia , Hyperinsulinism , Intra-Abdominal Fat/metabolism , Isomerism , Linoleic Acids, Conjugated/chemistry , Male , Obesity/prevention & control , PPAR gamma/metabolism , Rats, WistarABSTRACT
The main aim of the present study was to investigate the effects of dietary trans-10, cis-12-conjugated linoleic acid (t10c12-CLA) on intestinal microbiota composition and SCFA production. C57BL/6 mice (n 8 per group) were fed a standard diet either supplemented with t10c12-CLA (0·5 %, w/w) (intervention) or with no supplementation (control), daily for 8 weeks. Metabolic markers (serum glucose, leptin, insulin and TAG, and liver TAG) were assessed by ELISA commercial kits, tissue long-chain fatty acids and caecal SCFA by GC, and microbial composition by 16S rRNA pyrosequencing. Dietary t10c12-CLA significantly decreased visceral fat mass (P< 0·001), but did not affect body weight (intervention), when compared with no supplementation (control). Additionally, lipid mass and composition were affected by t10c12-CLA intake. Caecal acetate, propionate and isobutyrate concentrations were higher (P< 0·05) in the t10c12-CLA-supplemented group than in the control group. The analysis of the microbiota composition following 8 weeks of t10c12-CLA supplementation revealed lower proportions of Firmicutes (P= 0·003) and higher proportions of Bacteroidetes (P= 0·027) compared with no supplementation. Furthermore, t10c12-CLA supplementation for 8 weeks significantly altered the gut microbiota composition, harbouring higher proportions of Bacteroidetes, including Porphyromonadaceae bacteria previously linked with negative effects on lipid metabolism and induction of hepatic steatosis. These results indicate that the mechanism of dietary t10c12-CLA on lipid metabolism in mice may be, at least, partially mediated by alterations in gut microbiota composition and functionality.
Subject(s)
Anti-Obesity Agents/adverse effects , Dietary Supplements/adverse effects , Fatty Acids, Volatile/metabolism , Intestinal Mucosa/microbiology , Intestines/microbiology , Linoleic Acids, Conjugated/adverse effects , Microbiota , Adiposity , Animals , Bacteroidetes/classification , Bacteroidetes/growth & development , Bacteroidetes/isolation & purification , Bacteroidetes/metabolism , Biomarkers/analysis , Biomarkers/blood , Biomarkers/metabolism , Cecum , Fatty Acids, Volatile/analysis , Gastrointestinal Contents/chemistry , Gastrointestinal Contents/microbiology , Intestinal Mucosa/metabolism , Intra-Abdominal Fat/pathology , Liver/metabolism , Liver/pathology , Male , Mice, Inbred C57BL , Molecular Typing , Non-alcoholic Fatty Liver Disease/etiology , Non-alcoholic Fatty Liver Disease/metabolism , Non-alcoholic Fatty Liver Disease/microbiology , Non-alcoholic Fatty Liver Disease/pathology , Organ SizeABSTRACT
Dietary conjugated linoleic acid (CLA) reduces indicators of early renal disease progression and the associated elevated cyclooxygenase (COX) levels in young obese rats with obesity-associated nephropathy (OAN). Therefore, renal function and injury and COX and its metabolites were assessed in obese fa/fa Zucker rats with more advanced renal disease. Obese rats at 16 weeks of age were provided with either cis(c)9, trans(t)11 (fa/fa-9,11) or t10,c12 (fa/fa-10,12) CLA for 8 weeks, and compared to lean (lean-CTL) and obese (fa/fa-CTL) rats provided the control diet without CLA. Obese rats displayed significantly reduced renal function and increased renal injury compared to lean rats. In the obese rat groups, glomerular hypertrophy was reduced in both CLA-supplemented groups. While all other measures of renal function or injury were not different in fa/fa-9,11 compared to fa/fa-CTL rats, the fa/fa-10,12 rats had greater renal hypertrophy, glomerular fibrosis, fibrosis, tubular casts and macrophage infiltration compared to the fa/fa-CTL and fa/fa-9,11 groups. The fa/fa-10,12 group also had elevated levels of renal COX1, which was associated with increased levels of two oxylipins produced by this enzyme, 6-keto-prostaglandin F(1α), and thromboxane B2. Renal linoleic acid and its lipoxygenase products also were lower in obese compared to lean rats, but CLA supplementation had no effect on these or any other lipoxygenase oxylipins. In summary, supplementation with c9,t11 CLA did not improve more advanced OAN and t10,c12 CLA worsened the renal pathology. Altered production of select COX1 derived oxylipins was associated with the detrimental effect of the t10,c12 isomer.
Subject(s)
Aging , Dietary Supplements/adverse effects , Kidney/pathology , Linoleic Acids, Conjugated/adverse effects , Obesity/physiopathology , Oxylipins/agonists , Renal Insufficiency/etiology , 6-Ketoprostaglandin F1 alpha/agonists , 6-Ketoprostaglandin F1 alpha/antagonists & inhibitors , 6-Ketoprostaglandin F1 alpha/metabolism , Animals , Cyclooxygenase 1/metabolism , Disease Progression , Fibrosis , Hypertrophy , Kidney/immunology , Kidney/metabolism , Kidney/physiopathology , Macrophage Activation , Membrane Proteins/agonists , Membrane Proteins/antagonists & inhibitors , Membrane Proteins/metabolism , Obesity/immunology , Oxylipins/antagonists & inhibitors , Oxylipins/metabolism , Rats, Zucker , Renal Insufficiency/metabolism , Renal Insufficiency/pathology , Renal Insufficiency/physiopathology , Severity of Illness Index , Thromboxane B2/agonists , Thromboxane B2/antagonists & inhibitors , Thromboxane B2/metabolismABSTRACT
Different dietary interventions have been identified as potential modifiers of adiponectin concentrations, and they may be influenced by lipid intake. We identified studies investigating the effect of dietary lipids (type/amount) on adiponectin concentrations in a systematic review with meta-analysis. A literature search was conducted until July 2013 using databases such as Medline, Embase and Scopus (MeSH terms: 'adiponectin', 'dietary lipid', 'randomized controlled trials (RCT)'). Inclusion criteria were RCT in adults analysing adiponectin concentrations with modification of dietary lipids. Among the 4930 studies retrieved, fifty-three fulfilled the inclusion criteria and were grouped as follows: (1) total dietary lipid intake; (2) dietary/supplementary n-3 PUFA; (3) conjugated linoleic acid (CLA) supplementation; (4) other dietary lipid interventions. Diets with a low fat content in comparison to diets with a high-fat content were not associated with positive changes in adiponectin concentrations (twelve studies; pooled estimate of the difference in means: -0·04 (95% CI -0·82, 0·74) µg/ml). A modest increase in adiponectin concentrations with n-3 PUFA supplementation was observed (thirteen studies; 0·27 (95% CI 0·07, 0·47) µg/ml). Publication bias was found by using Egger's test (P= 0·01) and funnel plot asymmetry. In contrast, CLA supplementation reduced the circulating concentrations of adiponectin compared with unsaturated fat supplementation (seven studies; -0·74 (95% CI -1·38, -0·10) µg/ml). However, important sources of heterogeneity were found as revealed by the meta-regression analyses of both n-3 PUFA and CLA supplementation. Results of new RCT would be necessary to confirm these findings.
Subject(s)
Adiponectin/blood , Dietary Fats/administration & dosage , Up-Regulation , Adiponectin/agonists , Adult , Diet, Fat-Restricted , Diet, High-Fat/adverse effects , Dietary Fats/therapeutic use , Dietary Supplements/adverse effects , Down-Regulation , Fatty Acids, Omega-3/therapeutic use , Humans , Linoleic Acids, Conjugated/adverse effects , Linoleic Acids, Conjugated/therapeutic use , Randomized Controlled Trials as Topic , Reproducibility of ResultsABSTRACT
The aim of the present study was to perform a short-term safety evaluation of dietary mono-conjugated α-linolenic acid isomers (CLNA; c9-t11-c15-18:3+c9-t13-c15-18:3) using a neonatal pig model. CLNA diet was compared with three other dietary fats: (1) conjugated linoleic acid (CLA; c9-t11-18:2+t10-c12-18:2), (2) non-conjugated n-3 PUFA and (3) n-6 PUFA. Thirty-two piglets weaned at 3 weeks of age were distributed into four dietary groups. Diets were isoenergetic and food intake was controlled by a gastric tube. Mono-CLNA diet did not significantly change body or organ weight, carcass composition and most biochemical parameters including; glucose, cholesterol, triglycerides, creatinine, blood urea nitrogen, hepatic enzymes and electrolytes levels in blood (P⩾0.09). Conversely, the n-3 PUFA composition of the brain, liver and heart decreased by 6-21% in the CLNA-fed group compared to animals fed nonconjugated n-3 PUFA (P<0.01). Responses to dietary treatments were tissue-specific, with the liver and the brain being the most deprived in n-3 PUFA. Our results support that short-term intake of mono-CLNA is safe in neonatal pigs but n-3 PUFA reduction in tissues deserves to be further investigated before using long-term nutritional supplementation in pigs and other animal models and before moving to clinical trials.